Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 3/20 | 0.71 |
| ▸ | BRAF | P15056 | 5/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.62 |
| ▸ | MEN1 | O00255 | 4/20 | 0.62 |
| ▸ | POLB | P06746 | 4/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | GSK3A | P49840 | 2/20 | 0.57 |
| ▸ | GSK3B | P49841 | 2/20 | 0.57 |
| ▸ | RET | P07949 | 2/20 | 0.54 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.51 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12632706 | 0.90 | GSK3A (0.61) | PIK3CGBRAFKMT2AMEN1POLB | |
| SCHEMBL6397908 | 0.87 | BRAF (0.69) | PIK3CGBRAFKMT2AMEN1POLB | |
| SCHEMBL3760822 | 0.83 | PIK3CG (0.61) | PIK3CGBRAFKMT2AMEN1POLB | |
| SCHEMBL3760817 | 0.83 | PIK3CG (0.61) | PIK3CGBRAFKMT2AMEN1POLB | |
| SCHEMBL3760819 | 0.83 | PIK3CG (0.61) | PIK3CGBRAFKMT2AMEN1POLB | |
| SCHEMBL15299526 | 0.83 | PIK3CG (1.00) | PIK3CGKMT2AMEN1POLBL3MBTL1 | |
| SCHEMBL6393236 | 0.83 | PIK3CG (1.00) | PIK3CGKMT2AMEN1POLBL3MBTL1 | |
| SCHEMBL6393214 | 0.83 | PIK3CG (1.00) | PIK3CGKMT2AMEN1POLBL3MBTL1 | |
| SCHEMBL3771633 | 0.83 | GSK3A (0.80) | PIK3CGBRAFKMT2AMEN1POLB | |
| SCHEMBL31358762 | 0.81 | PIK3CG (0.60) | PIK3CGBRAFKMT2AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008002641-A2 | PROTEIN PHOSPHATASE INHIBITORS | THE CLEVELAND CLINIC FOUNDATION (US) | 2008-01-03 | — | — | WO | disclosed |
| EP-1718308-A4 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORP (CA) | 2007-07-18 | — | — | EP | disclosed |
| EP-1718308-A2 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PainCeptor Pharma Corp. (CA) | 2006-11-08 | — | — | EP | disclosed |
| US-20050282840-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2005-12-22 | — | — | US | disclosed |
| WO-2005076695-A2 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORPORATION (CA) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282840-A1 | Methods of modulating neurotrophin-mediated activity | NGF, BDNF, NTRK2 | PIK3CG 2749/4885BRAF 4079/4885KMT2A 4410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.